American Association for Cancer Research
Browse
00085472can152194-sup-153980_1_supp_3295794_90gn4k.png (92.58 kB)

Supplemental Figure 7 from JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma

Download (92.58 kB)
figure
posted on 2023-03-31, 00:04 authored by Tiffany Sin Yu Chan, Cynthia Hawkins, Jonathan R. Krieger, C. Jane McGlade, Annie Huang

AKT inhibition does not alter JPO2 mRNA levels

Funding

Canadian Institute of Health Research

History

ARTICLE ABSTRACT

Substantial evidence links Myc–PI3K/AKT signaling to the most aggressive subtype of medulloblastoma and this axis in medulloblastoma therapy. In this study, we advance understanding of how Myc–PI3K/AKT signaling contributes to this malignancy, specifically, in identifying the Myc-interacting protein JPO2 and its partner binding protein LEDGF/p75 as critical modulators of PI3K/AKT signaling and metastasis in medulloblastoma. JPO2 overexpression induced metastatic medulloblastoma in vivo through two synergistic feed-forward regulatory circuits involving LEDGF/p75 and AKT that promote metastatic phenotypes in this setting. Overall, our findings highlight two novel prometastatic loci in medulloblastoma and point to the JPO2:LEDGF/p75 protein complex as a potentially new targetable component of PI3K/AKT signaling in medulloblastoma. Cancer Res; 76(9); 2802–12. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC